Blog
RSS FeedPosted by Michael Wonder on 31 May 2017
Kineret approved in Canada for the treatment of neonatal-onset multisystem inflammatory disease (NOMID)
30 May 2017 - Sobi Canada today announces that Health Canada has approved Kineret (anakinra) for the treatment of neonatal-onset ...
Posted by Michael Wonder on 27 May 2017
Piramal Imaging and IsoLogic Innovative Radiopharmaceuticals announce commercial approval of Neuraceq by Health Canada
28 February 2017 - Piramal Imaging and IsoLogic Innovative Radiopharmaceuticals today announce that Health Canada has issued a Notice of ...
Posted by Michael Wonder on 26 May 2017
Health Canada grants approval for Ocaliva (obeticholic acid) for the treatment of patients with primary biliary cholangitis
25 May 2017 - Ocaliva represents the first new treatment option in over 20 years for primary biliary cholangitis, an ...
Posted by Michael Wonder on 18 May 2017
Health Canada approves Opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck
17 May 2017 - Latest approval of Opdivo marks the fourth indication for the immuno-oncology treatment offering hope for improved ...
Posted by Michael Wonder on 17 May 2017
Viberzi now approved in Canada for patients with irritable bowel syndrome with diarrhoea
May 16 2017 - Allergan is pleased to announce the Health Canada approval of Viberzi (eluxadoline) for the treatment of ...
Posted by Michael Wonder on 09 May 2017
Cipher Pharmaceuticals receives Health Canada approval of Ozanex (ozenoxacin 1% cream)
8 May 2017 - Cipher Pharmaceuticals today announced the Health Canada approval of Ozanex (ozenoxacin 1% cream) a novel topical ...
Posted by Michael Wonder on 07 May 2017
ALK's HDM SLIT-tablet Acarizax approved in Canada
4 May 2017 - ALK today announced that its house dust mite sub-lingual allergy immunotherapy tablet Aacazix has been approved ...
Posted by Michael Wonder on 02 May 2017
Sanofi Genzyme announces approval of Cerdelga (eliglustat tartrate) by Health Canada for rare genetic condition
1 May 2017 - Sanofi Genzyme announced today that Health Canada has recently approved Cerdelga (eliglustat capsules), the only first-line ...
Posted by Michael Wonder on 19 Apr 2017
Health Canada approves Tecentriq (atezolizumab) for patients with locally advanced and metastatic bladder cancer
18 April 2017 - Early data suggests Tecentriq shows strong efficacy for metastatic bladder cancer patients, offering the first new ...
Posted by Michael Wonder on 18 Apr 2017
Janssen receives Health Canada approval of Darzalex (daratumumab) by priority review for patients with multiple myeloma who have had at least one prior therapy
17 April 2017 - Darzalex combination therapy significantly improved progression-free survival compared to standard of care regimens alone. ...
Posted by Michael Wonder on 29 Mar 2017
New fast-acting mealtime insulin, Fiasp, now approved and available in Canada for the treatment of diabetes
27 March 2017 - Faster absorption of insulin key for Canadians living with diabetes. ...
Posted by Michael Wonder on 16 Mar 2017
Cardiome receives Notice of Compliance from Health Canada for its Brinavess NDS
14 March 2017 - Cardiome Pharma Corporation announced today that it received a Notice of Compliance for Brinavess (vernakalant hydrochloride, IV) ...
Posted by Michael Wonder on 15 Mar 2017
Ipsen announces Health Canada approval of Dysport Therapeutic (abobotulinumtoxinA) for the treatment of patients with cervical dystonia and adult upper limb spasticity
14 March 2017 - Ipsen Biopharmaceuticals Canada today announced that Health Canada has approved Dysport Therapeutic (abobotulinumtoxinA) for the treatment ...
Posted by Michael Wonder on 18 Feb 2017
Health Canada approves Otsuka and Lundbeck's Rexulti (brexpiprazole) as a treatment for schizophrenia in adults
17 February 2017 - Otsuka and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for Rexulti (brexpiprazole) ...
Posted by Michael Wonder on 17 Feb 2017
Gilead receives approval in Canada for Odefsey for the treatment of HIV-1 infection
16 February 2017 - Odefsey is the second single tablet regimen containing the Descovy backbone and the third product in ...